Abstract Body

Topical on-demand HIV prevention modalities are a desirable alternative to daily oral or long-acting injectable PrEP. CONRAD has developed inserts containing tenofovir alafenamide (TAF) and elvitegravir (EVG) for on-demand vaginal or rectal pericoital use, which are currently in early clinical testing. TAF/EVG inserts provided high protection as PrEP or PEP in pigtailed macaques exposed vaginally to simian HIV (SHIV). We recently reported on the pharmacokinetics of the same inserts when applied rectally. Here, we assessed the efficacy of 1 or 2 inserts against rectal SHIV transmission in a repeat low-dose SHIV challenge model in pigtailed macaques.

Macaques were challenged rectally with low-dose SHIV162p3 4h after application of 1 or 2 TAF/EVG (20 mg/16 mg) inserts (n=6 per group). Single inserts and virus inoculums were placed at 4 cm from the anal sphincter. For 2 inserts, the second insert was placed 8 cm deep. Animals were challenged once weekly with SHIV162P3 for up to 10 weeks. Efficacy was estimated for 1 or 2 TAF/EVG inserts. Time to infection was compared to 6 placebo animals using the log rank test. Drug concentrations (EVG and TFV-DP) in rectal tissues were measured 4h after insert application by HPLC MS/MS.

Median rectal tissue EVG and TFV-DP levels with 1 insert at 4h were 8128 ng/mg (range=BLQ–515,053) and 2187 fmol/mg (range=411–2500), respectively. With 2 inserts, EVG and TFV-DP were approximately one log higher compared with 1 insert (EVG 73,708 ng/mg; range BLQ–271,316 and TFV-DP 66,553 fmol/mg; range 2801–540,823). The single TAF/EVG insert arm was terminated after 6 exposures given the high rate of infection (4/6 infected at exposures 2, 3, 4, and 4). However, the time to infection was significantly delayed when compared to the placebo controls (p=0.0046). Calculated efficacy was 72.6% (95% exact CI =24.5%, 92.7%). With 2 inserts and 10 virus challenges, 2/6 animals became infected at exposures 2 and 8 resulting in 93.1% (95% CI=73.2%, 99.2%) efficacy (p=0.0022).

Despite similar tissue drug levels after vaginal and rectal application, a single TAF/EVG insert only achieved moderate protection after rectal challenge. Adding a second insert increased drug distribution through rectal tissues and boosted efficacy to 93%. Collectively, these data document pharmacodynamic differences between rectal and vaginal mucosa, informing insert dose selection in both compartments for advanced clinical development.